Background. We investigated clinicopathologic features in patients with esophageal small cell carcinoma (SCEC), and its proliferative activity and angiogenesis. Methods. Ten patients with SCEC from 335 esophageal carcinoma patients were analyzed clinicopathologically. For analyses of cell proliferation, apoptosis, and angiogenesis of SCEC, Ki-67 immunostaining, the TUNEL method, and CD31 and CD68 immunostaining were used. Results. Esophagectomy was performed in nine patients, while one with extensive SCEC was treated by repeated chemotherapy and radiotherapy. Four patients received chemotherapy both before and after surgery, one only before surgery, and four only after surgery. Cisplatin and etoposide were given to fi ve patients, while irinotecan and cisplatin were given to three. Five survived more than 18 months, and two more than 36 months. One of these two had limited SCEC treated by surgery and chemotherapy, whereas the other had extended SCEC treated by repeated chemotherapy and radiotherapy. The microvessel count and the Ki-67 labeling index of SCEC were higher than those of squamous cell carcinoma (P = 0.0033 and P = 0.0005, respectively). Between SCEC with and without preoperative chemotherapy, the Ki-67 labeling index was lower (P = 0.027) and the apoptotic index was higher in the treated SCEC (P = 0.014). Between SCEC patients who survived more or less than 18 months, the microvessel count was lower in those who survived more than 18 months (P = 0.049). Conclusions. Esophagectomy may be indicated for limited SCEC combined with chemotherapy. SCEC has high proliferative activity and rich neovascularization, and its proliferative activity may be suppressed by chemotherapy.
Introduction
Small cell carcinoma is a rare entity in the esophagus; it accounts for approximately 1% of all carcinomas of the esophagus and the gastric cardia, 1,2 but is more frequently observed in the esophagus than elsewhere in the gastrointestinal tract. 3 Small cell carcinoma of the esophagus (SCEC) has been associated with a poor prognosis, being similar to small cell lung carcinoma (SCLC). 2, 4 To improve the clinical outcome in SCEC patients, multidisciplinary approaches to treatment, including the use of chemotherapy, may be necessary. 2, 4, 5 However, various diagnostic and therapeutic issues remain in SCEC patients. In SCLC patients, combination chemotherapy with irinotecan and cisplatin (CPT/ P) has a better survival benefi t than that with cisplatin and etoposide (PVP). 6 For SCEC patients, combination chemotherapy with PVP, similar to chemotherapy for SCLC patients, has been available. 7 It is well known that proliferative activity of tumor cells and angiogenesis in tumor stroma play important roles in tumor progression and metastasis. 8, 9 Although biological characteristics regarding proliferative activity of tumor cells and angiogenesis have been well investigated in squamous cell carcinoma (SCC) of the esophagus 10, 11 and in SCLC, 12, 13 we found only a few reports of investigations of proliferative activity of SCEC, 14, 15 and we found no report of an investigation of angiogenesis in SCEC. Ki-67 immunohistochemistry has been used to evaluate the proliferative activity of tumor cells, and the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate biotin nick-end labeling (TUNEL) method 16 has been used to evaluate of tumor cell apoptosis. 10, 11 Furthermore, microvessel density has been used to evaluate tumor angiogenesis, 17 and infi ltrating macrophages to evaluate angiogenesis caused by interaction between tumor and stromal cells. 18 We retrospectively investigated clinicopathologic features of SCEC in ten patients who were treated by surgery, chemotherapy, and/or radiotherapy, and their therapeutic issues. Furthermore, we histochemically analyzed proliferative activity and angiogenesis in SCEC.
Methods

Patients
Among 335 patients with primary carcinoma of the thoracic esophagus who were treated between 1991 and 2005 in Shinshu University Hospital, ten (3.1%) with SCEC were treated by surgery, chemotherapy, and/or radiotherapy. The cases of three of these have already been reported. 7, 19 We retrospectively reviewed the cases of the ten patients and investigated their clinicopathologic features, including surgery and chemotherapy, and the clinical outcome after initial treatment for SCEC. As chemotherapy for SCEC, the combination CPT/P had been prospectively given to three recent patients before and/or after surgery because Noda et al. 6 reported that CPT/P contributed to a better prognosis than PVP in SCLC patients.
SCEC was diagnosed histopathologically by using formalin-fi xed and paraffi n-embedded sections of biopsy specimens taken endoscopically from the tumors and/or from resected specimens after surgery. Not only hematoxylin and eosin staining but also immunohistochemical staining for chromogranin A, neuron-specifi c enolase, synaptophysin, or other neuroendocrine markers was used. The clinicopathologic fi ndings of the esophageal carcinomas were described according to the TNM classifi cation (6th edition). 20 
Histochemical analyses
SCEC tissue samples were obtained from the nine of the ten patients who underwent esophagectomy for histochemical analyses of proliferative activity and angiogenesis as well as for routine histopathologic examination. These tissues were fi xed in 10% formalin buffered with phosphate at pH 7.4 and embedded in paraffi n. To determine the proliferative activity of SCEC, Ki-67 immunostaining was performed using an anti-Ki-67 monoclonal antibody (MIB1, diluted 1 : 100; Immunotech, Marseille, France) on sections treated in a microwave oven before the staining treatment. The percentage of tumor cells with nuclei stained by Ki-67, that is, the Ki-67 labeling index, was calculated for each section on the basis of about 2000 tumor cell nuclei. 10 TUNEL, used to assess apoptosis, was used according to the method of Gavrieli et al. 16 and our previous report. 10 The TUNEL reaction was visualized with 3,3′-diaminobenzidine tetrachloride (DAB), and a dark accumulation of DAB in the cancer cells (nuclei and apoptotic bodies) was judged to indicate a positive reaction to TUNEL. The percentage of TUNEL-positive cells, that is, the apoptotic index, was calculated for each section on the basis of about 2000 tumor cells. 10 To evaluate tumor angiogenesis, immunohistochemical staining for CD31 and CD68 antigens was performed. The avidin-biotin complex method was used, and the monoclonal antibodies used for this immunostaining were anti-human CD31 antibody (JC70A, diluted 1 : 100; Genezyme Techne, Minneapolis, MN, USA) and antihuman CD68 antibody (KP1, diluted 1 : 100; Dako, Glostrup, Denmark) for CD31 and CD68, respectively. Microvessels in the tumor stroma in the CD31-stained sections were counted, and the microvessel count was determined according to the method of Maeda et al. 17 Macrophages, identifi ed by CD68 immunohistochemistry, were counted as stromal monocytes (monocytic count).
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For comparison with the histochemical results mentioned above, we examined cases of 44 patients with SCC of the esophagus who underwent curative esophagectomy with neither preoperative chemotherapy nor radiotherapy between 1995 and 2002 in Shinshu University Hospital.
Statistical analyses
The clinicopathologic features and histochemical results were analyzed by the χ-squared test or Fisher's exact probability test, and the Mann-Whitney U test. Statistical signifi cance was defi ned as P < 0.05.
Results
Clinicopathologic features
The clinicopathologic features of the ten patients with SCEC are shown in Tables 1 and 2 . Curative esophagectomy with two-or three-fi eld lymph node dissection was performed in nine of the ten patients, while only one patient (case 10) did not undergo surgery but received chemoradiotherapy because SCEC had directly invaded the aorta. Chemotherapy for SCEC was performed in all patients; four were treated both before and after surgery, one was treated only before surgery, and four were treated only after surgery. Alternative chemotherapy consisting of PVP, and cyclophosphamide, adriamycin (or epirubicin), and vincristine (CAV) 
Ex, esophagectomy with lymph node dissections; PVP, cisplatin and etoposide; CAV, cyclophosphamide, adriamycin, and vincristine; CEV, cyclophosphamide, epirubicin, and vincristine; 5FU, 5-fl uorouracil; CBDCA, carboplatin; CDDP, cisplatin; CPT, irinotecan was given to three and four patients, before and after surgery, respectively. The most recent three patients (cases 8-10) received chemotherapy with CPT/ P. External beam radiotherapy for primary or metastatic tumors was performed in fi ve patients. The patient who had SCEC with direct invasion to the descending aorta (T4) received PVP/CAV therapy as well as radiotherapy. Three patients were given adjuvant radiotherapy after surgery. In case 10, without esophagectomy, radiotherapy was performed for the primary tumor and metastatic nodes of the abdomen after CPT/P therapy.
Clinical outcome
None of the patients had distant metastasis at the time of detection of the esophageal tumor; however, in nine patients, distant metastases to several organs were detected after the initial treatment, including chemoand/or radiotherapy and surgery. Only two patients survived more than 36 months; one had limited SCEC treated by surgery and postoperative chemotherapy with PVP/CAV, and the other had extensive SCEC treated repeatedly by chemotherapy with CPT/P and radiotherapy. Survival after the initial treatment ranged from 7 to 80 months; the median survival was 13.0 months, and the mean survival was 22.7 months. Five patients, including case 10 without surgery, survived over 18 months after the initial treatment. In three of the fi ve patients, no nodal metastasis was observed: one without preoperative chemotherapy (case 7) had no nodal metastasis, whereas a complete response in the nodes was found histologically after surgery in the other two (cases 3 and 4). For all patients, the 1-year and 5-year survival rates were 60.0% and 20.0%, respectively.
Histochemical analyses
The Ki-67 immunostaining, TUNEL, and CD31 and CD68 immunostaining fi ndings are shown in Fig. 1 . The Ki-67 labeling index in SCEC was higher than that in SCC (56.6 ± 5.9% vs. 48.4 ± 6.3%; P = 0.0033; Fig. 2A ).
There was no statistical difference in the apoptotic index between SCEC and SCC (1.5 ± 0.50% vs. 1.6 ± 0.65%; Fig. 2B ). The microvessel count of SCEC was higher than that of SCC (50.7 ± 18.5 vs. 27.2 ± 11.6; P = 0.0005; Fig. 2C ), but there was no statistical difference between SCEC and SCC in the monocytic count (137.0 ± 79.4 vs. 188.8 ± 105.6; Fig. 2D ). We also compared these histochemical results between SCEC with and without preoperative chemotherapy. The Ki-67 labeling index of SCEC with chemotherapy was lower than that without it (52.6 ± 4.4% vs. 61.6 ± 2.7%; P = 0.027; Fig. 2E ), and the apoptotic index of SCEC with chemotherapy was higher than that without it (1.9 ± 0.32% vs. 1.1 ± 0.21%; P = 0.014; Fig. 2F ). We found no statistical difference in the microvessel count, although it tended to be higher in SCEC without chemotherapy than in that with it (64.9 ± 20.2 vs. 39.3 ± 4.4; Fig. 2G ). The monocytic count did not differ statistically between SCEC without and with chemotherapy (164.2 ± 81.4 vs. 115.6 ± 71.9; Fig. 2H ). We compared the histochemical results between SCEC patients who survived longer than and those who survived less than 18 months after initial treatment. The microvessel count in patients who survived more than 18 months was lower than that in those who survived less than 18 months (38.5 ± 5.2 vs. 60.4 ± 20.0; P = 0.049; Fig. 2K ), whereas the Ki-67 labeling index, the apoptotic index, and the monocytic count did not differ statistically between these groups (53.5 ± 6.7% vs. 59.1 ± 4.4%, Fig. 2I ; 1.7 ± 0.58% vs. 1.4 ± 0.45%, Fig. 2J ; 146.8 ± 114.1 vs. 129.5 ± 51.8, Fig. 2L, respectively) .
Discussion
It is controversial whether surgery is necessary although chemotherapy plays a key role in the treatment of SCEC patients. Casas et al. 5 reported that surgery alone was the single most powerful predictor of death in SCEC patients. There is some evidence that surgery for limited SCEC might improve long-term survival; some patients with SCEC who were treated by surgical resection combined with chemotherapy have been reported to survive for more than 5 years. 21, 22 In our series, only one patient is alive without recurrence more than 5 years after surgery. The four SCEC patients with surgery who survived more than 18 months showed no pathologic nodal metastases in the resected specimens. One patient (case 7) without recurrence had no nodal metastasis, which was diagnosed clinically and pathologically, and there was no nodal metastasis pathologically in the other three patients who received preoperative chemotherapy, although nodal metastases were present in the mediastinum before chemotherapy. However, in the other esophagectomized patients who died of metastatic SCEC within 18 months of the initial treatment, nodal metastases were pathologically demonstrated despite preoperative chemotherapy. Therefore, surgery may contribute to long-term survival of patients with SCEC without nodal metastases, such as limited SCEC; however, SCEC patients with nodal metastasis have a better chance of long-term survival if the nodal metastasis is controlled or cured by chemotherapy or radiotherapy before surgery. Several authors have reported that chemotherapy is needed for improvement of survival in SCEC patients. 3, 5 Combination chemotherapy with CPT/P for SCEC has been occasionally reported recently, 23 whereas previously the combination with PVP was frequently used. 7 Because no standard regimen has been established for SCEC, several regimens, based on well-researched SCLC regimens in many SCLC patients, have been used. Although the PVP regimen was frequently used in the patients of this study treated before 2002 (cases 1-7), we prospectively changed the chemotherapeutic regimen from PVP therapy to CPT/P therapy on the basis of a report that CPT/P contributed to a better prognosis than PVP in SCLC patients. 6 The fact that one patient (case 10) with extensive SCEC, who was repeatedly treated with chemotherapy with CPT/P, showed long-term survival is very interesting. A large study to assess whether this regimen can play a key role in terms of survival benefi t in SCEC patients is needed.
Radiation frequently induces the clinical response of SCEC regression. 24, 25 Radiotherapy has been adopted for extensive SCEC, and radiotherapy has contributed to an improvement in the prognosis in cases of limited SCEC. 25 In our series, T4 SCEC, such as case 1, was down staged to T2 after extra-beam radiotherapy, and the SCEC was surgically removed. In extensive SCEC such as case 10, with locally advanced SCEC and widespread node metastases, radiotherapy for local foci and nodal metastasis may control tumor progression when surgery is not indicated. Although radiotherapy may locally induce regression of SCEC, it should be combined with systemic chemotherapy to improve survival.
The prognosis of SCEC patients is usually poor. In previous reports, the median survival of patients with SCEC ranged from 3 to 7.5 months. 1, 2, 4 In recent reports, survival is slightly prolonged, but most patients with SCEC, especially those with extensive SCEC, still have a poor prognosis. 26 In the present study, although the median survival was 13 months, fi ve patients survived more than 18 months after the initial treatment and two With regard to the proliferative activity of tumor cells, high proliferative activity of SCLC has been demonstrated, as immunohistochemically evaluated by the Ki-67 labeling index. 12 Lam et al. 15 reported Ki-67 labeling indexes of SCEC similar to the present results in that the mean value was 56%. In the present study, the Ki-67 labeling index of SCEC was higher than that of esophageal SCC; the aggressive nature of SCEC is evidenced by these data. Furthermore, chemotherapy may suppress SCEC progression, because the Ki-67 labeling index of SCEC treated with chemotherapy was lower than that not treated with chemotherapy. On the other hand, apoptosis plays an essential role in tumor progression, including in esophageal carcinomas. 10 Although there are a few reports regarding p53 overexpression 15 and Bcl-2 positivity 27 in SCEC, there are none regarding the SCEC apoptotic index. In the present study, the SCEC apoptotic index was lower than that of esophageal SCC. Furthermore, the apoptotic index of SCEC treated with chemotherapy was higher than that of SCEC not treated. Taken together, these data on the Ki-67 labeling index and apoptotic index suggest that chemotherapy plays an important role in SCEC treatment, even when proliferative activity is very high.
Angiogenesis also plays an important rule in tumor progression and metastasis. 8 In the present study, angiogenesis in SCEC was assessed by the microvessel and monocytic counts. In esophageal SCC, we previously reported that not only angiogenesis assessed by the microvessel count but also angiogenic promotion assessed by the monocytic count, as well as the status of macrophage infi ltration into the tumor stroma, are necessary to assess tumor progression and metastasis. 10, 11 Angiogenesis in SCLC has been well analyzed, 13 but no report has described neovascularization and macrophage infi ltration in the stroma in SCEC. Angiogenesis, as evaluated by the microvessel count, in SCEC may be more vigorous than that in esophageal SCC, although macrophage infi ltration, which may induce angiogenic promotion by releasing several cytokines and angiogenic growth factors, is not higher than that of esophageal SCC. This high neovascularization may infl uence aggressive behavior, including distant metastases, of SCEC. SCEC treated with chemotherapy or cases associated with long-term survival had a lower microvessel count. Therefore, it is clear that chemotherapy is an important treatment for SCEC.
In conclusion, surgery combined with chemotherapy may be indicated for limited SCEC, and surgery may be additionally indicated for SCEC when nodal metastasis is controlled or cured by chemotherapy. SCEC showed high proliferative activity and rich neovascularization, and these biologic features may infl uence its clinicopathologic aggressiveness. Its proliferative activity is suppressed by chemotherapy, so chemotherapy may improve patient outcomes.
